Dr. Anjaneyulu Muragundla, Ph.D
Director, Pharmacology & Toxicology
Dr. Anjaneyulu Muragundla brings over 25 years of experience in preclinical drug discovery and development across global biotech, pharmaceutical, and academic research environments. At Aryastha, he leads the Pharmacology & Toxicology function, overseeing the design, execution, and delivery of preclinical studies that support discovery programs and translational research across therapeutic areas.
His scientific expertise spans in-vitro and in-vivo pharmacology, toxicology evaluations, molecular biology, target identification and validation, and AI/ML-enabled drug discovery and repurposing. Over the course of his career, he has played key roles in more than 30 international client programs, including IND-enabling toxicology studies, and has significantly contributed to establishing high-quality preclinical workflows and testing platforms.
Before joining Aryastha, Dr. Muragundla held senior scientific and leadership positions at InveniAI (BioXcel Corporation Ltd.), Syngene International Ltd., Abbott Nutrition R&D, and Torrent Pharmaceuticals. He completed post-doctoral research at the University of Maryland and the University of Michigan, where he focused on mitochondrial mechanisms underlying diabetic neuropathy. His academic credentials include a Ph.D. in Pharmacology from Panjab University and an M.S. (Pharm) in Pharmacology & Toxicology from NIPER Mohali.
Dr. Muragundla has authored 38 scientific publications, contributed a book chapter on mitochondrial biogenesis in diabetic neuropathy, and received multiple prestigious international fellowships and awards, including recognitions from NIH, IBRO, ISN, and DST. He is also an active member of several scientific societies, including the American Diabetes Association and the Society for Neuroscience.
